According to a recent LinkedIn post from Astraveus, the company plans to showcase its Lakhesys manufacturing platform for CAR-T therapies at the ISCT 2026 meeting in Dublin. The post highlights a presentation and posters focused on a novel microfluidic approach aimed at optimizing and scaling CAR-T manufacturing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn content suggests Astraveus is positioning Lakhesys as a potential solution to balance speed, cost, quality, and scalability in cell therapy production. For investors, visible engagement at a specialized industry conference may signal ongoing product development, potential future partnerships, and efforts to validate the platform with a technical and commercial audience.
The participation of senior staff, including the COO and directors of product management and process science, points to strategic importance for the company’s roadmap. If the technology demonstrates meaningful efficiency or quality advantages, it could strengthen Astraveus’s competitive position in advanced therapy manufacturing and support future revenue opportunities in the cell and gene therapy ecosystem.